Navigation Links
Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
Date:5/9/2008

PRINCETON, N.J., May 9 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson has been appointed Chief Executive Officer. Mr. Jackson joined Celator in October 2007 as Head of Commercial Development.

"We are delighted to have Scott as the new CEO. He brings more than 20 years of pharmaceutical experience, including 10 years of specialty pharmaceutical experience primarily in oncology," said Dr. Joseph Mollica, Chairman of Celator's Board of Directors. "His senior management experience and commercial and clinical development knowledge will be extremely valuable to the organization as the company moves forward."

Mr. Jackson has extensive experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing, and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor (Johnson & Johnson), Eximias Pharmaceuticals and YM BioSciences. Mr. Jackson holds a B.S. in Pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Mr. Jackson succeeds Dr. Andrew Janoff.

"I'm very excited about the future for Celator Pharmaceuticals," said Mr. Jackson. "We have an entrepreneurial spirit and commitment at the company and I look forward to contributing to the company's growth and success."

"Celator has two promising products in clinical development based on the company's proprietary drug ratio technology platform, CombiPlex (TM). Results from a Phase 2 study of CPX-1 (a liposomal formulation of irinotecan:floxuridine) in patients with advanced colorectal cancer will be reported later this year at major medical conferences. Results from a Phase 1 study with CPX-351 (a liposomal formulation of cytarabine:daunorubicin) in patients with advanced leukemias will be submitted to a conference before the end of the year," said Mr. Jackson. "In addition, Celator's CombiPlex (TM) technology pl
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
(Date:8/27/2014)...   MSC , a healthcare performance improvement company ... appointment of Mary Beth Loesch to President ... experience preparing companies for rapid growth and market expansion, ... of Corporate Development and Healthcare. In that role, she ... well as corporate strategy and marketing. Previously, Loesch served ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... April 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX:,MS), ... sclerosis (MS), today,announced that the independent Data Safety ... on-going MAESTRO-03 U.S. pivotal phase III,clinical trial of ... and,recommended that the trial continue., This was ...
... Bionovo Inc.,(Nasdaq: BNVI ) will present findings on ... BN107 and BN108 at the American Association of,Cancer Research ... in San,Diego, CA, April 12 - 16, 2008., ... cell,apoptosis (cell death) induced by BN107 and BN108. As ...
... ST. JOSEPH, Mich., April 15 GeneGo, Inc., ... The Scripps,Translational Science Institute has joined the MetaMiner ... build the first systems,biology and pathway analysis platform ... will vote on deliverables that will include,disease specific ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research 2The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium 2
(Date:8/27/2014)... of studies have shown that excessive iron ... Parkinson,s disease. Previous studies from Chunyan Guo ... China have shown that baicalin prevented iron ... metal transporter 1 expression, and increased ferroportin ... rotenone-induced Parkinson,s disease rats. However, the relationship ...
(Date:8/27/2014)... that can be found in both unprocessed and processed ... Denmark have been infected with Listeria from ... The bacterium is notoriously difficult to fight because it ... in its surroundings, says Associate Professor Birgitte Kallipolitis, University ... of Biochemistry and Molecular Biology, she has published a ...
(Date:8/26/2014)... over a colony of harmful bacteria, biofilms make ... protected in a biofilm pose a significant health ... to treatment, and biofilm-protected bacteria account for some ... and are 50 to 1,000 times more resistant ... essence, we may have stumbled onto a magic ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... energy produced by cars, machines, and industry around the world ... but researchers have found a new way to make "thermoelectric" ... amounts of energy. And it,s based on a device ... Chemists at Oregon State University have discovered that simple ...
... team has turned their newly developed 3-D microscope technology ... use. U of A engineering professor Dileepan ... system called Virtual Reflected-Light Microscopy. The technology consists of ... that moves the objects being photographed and software programs ...
... Paul Kenis and James Slauch have been named ... university,s most talented teachers, scholars and researchers. Kenis, ... in the field of micro fluidics and the development ... health. These tools include the creation of evaporation-based ...
Cached Biology News:Microwave ovens a key to energy production from wasted heat 2Microwave ovens a key to energy production from wasted heat 3University of Illinois faculty members named University Scholars 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: